Cardiovascular disease in CKD

Cardiovascular Disease in CKD

Renal Association Clinical Practice Guideline on cardiovascular disease in CKD.

This clinical practice guideline provides recommendations on the prevention and management of cardiovascular disease in patients with chronic kidney disease (CKD) and serves as an update of the 4th edition module published online in 2007 (www.renal.org). The literature in the English language has been searched and reviewed to take account of studies that have been published between 2006 and Feb...

Cell Therapy in Cardiovascular Disease

  Recently, cell therapy has sparked a revolution in ischemic heart disease that will in the future help clinicians to cure patients. Earlier investigations in animal models and clinical trials have suggested that positive paracrine effects such as neoangiogenesis and anti-apoptotic can improve myocardial function. In this regard the Royan cell therapy center designed a few trials in collaborat...

The role of microRNAs in cardiovascular disease

Cardiovascular disease has become the main factor of death and birth defects in the world. There are some therapeutic structures and drugs for curative and palliative therapy of the disease, but to the aim of accessing reliable therapy or to postpone onset of disease, especially for individuals with heritable coronary artery disease in their pedigree Genetic engineering technologies are making...

Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?

Antiplatelet agents (APAs) are proven to reduce risk of major cardiovascular events in patients with cardiovascular disease and normal kidney function. With recent post hoc analyses of large trials questioning the safety and efficacy of APAs in CKD, major gaps exist in our understanding of platelet aggregability and the effects of APAs on thrombosis and bleeding in CKD. Clinical practice guidel...